Dutch biotech Crucell has inked a joint venture deal with MedImmune to develop its bacterial antibodies to treat hospital-acquired infections. MedImmune has agreed to provide upfront, annual and milestone fees that could exceed $40 million. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-medimmune-and-crucell-announce-collaboration